Allspring Global Investments Holdings LLC Has $1.01 Million Stake in Iradimed Corporation (NASDAQ:IRMD)

Allspring Global Investments Holdings LLC grew its holdings in Iradimed Corporation (NASDAQ:IRMD) by 14.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,122 shares of the medical equipment provider’s stock after purchasing an additional 2,538 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.16% of Iradimed worth $1,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of IRMD. Isthmus Partners LLC increased its holdings in shares of Iradimed by 880.8% during the first quarter. Isthmus Partners LLC now owns 71,905 shares of the medical equipment provider’s stock valued at $3,163,000 after acquiring an additional 64,574 shares in the last quarter. Liontrust Investment Partners LLP acquired a new position in shares of Iradimed during the second quarter valued at about $2,830,000. Roubaix Capital LLC bought a new stake in shares of Iradimed during the first quarter worth about $2,213,000. Kings Path Partners LLC bought a new position in Iradimed in the 2nd quarter valued at about $1,055,000. Finally, Sequoia Financial Advisors LLC acquired a new position in Iradimed during the 2nd quarter valued at about $568,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analyst Ratings Changes

Separately, Roth Mkm dropped their target price on Iradimed from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, August 2nd.

Iradimed Stock Performance

NASDAQ:IRMD opened at $49.27 on Friday. Iradimed Corporation has a 52 week low of $39.24 and a 52 week high of $53.99. The firm has a 50-day moving average price of $48.84 and a two-hundred day moving average price of $45.45. The firm has a market cap of $623.96 million, a price-to-earnings ratio of 35.04 and a beta of 0.79.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.05. The firm had revenue of $17.93 million during the quarter, compared to the consensus estimate of $17.70 million. Iradimed had a return on equity of 24.71% and a net margin of 26.83%. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, sell-side analysts forecast that Iradimed Corporation will post 1.41 earnings per share for the current year.

Iradimed Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.